SHIRLEY LANTREIBECQ

Accelerated market access for innovative oncologic drugs in Belgium and Luxembourg across a 6-year tenure, focusing on lung, GI, breast, hematologic and tumor-agnostic indications. Developed and executed comprehensive market access strategies for multiple indications, ensuring optimal positioning of oncology treatments. Drafted persuasive pricing and reimbursement dossiers, effectively communicating the value proposition of oncologic therapies to stakeholders. Constructed detailed patient flow analyses and pharmacoeconomic models, including budget impact and cost-effectiveness models, to support decision-making processes. Formulated robust business cases to facilitate managed entry agreements and price negotiations with BeLux health authorities and internal stakeholders.

During this 6-month assignment, I played a pivotal role in the development of a comprehensive value story and adoption ladder for a new drug aimed at addressing the medical needs of a specific population in breast cancer. This initiative involved collaborating with cross-functional teams to establish the clinical and economic value of the treatment, ensuring alignment with patient and stakeholder needs.

Driving force behind the global commercial performance enhancement, providing strategic direction to marketing and medical teams. Orchestrated the creation of a European Brand Plan and competitive intelligence tool, strengthening market positioning. Facilitated business development, provided hands-on support to European and Singaporean distributors. Designed commercial tender strategies and market access plans, optimizing regional growth opportunities.

• Developed a global strategy for a longstanding medical device, realigning team focus towards unified objectives.
• Innovated by developing a global iPad application, technical SOPs, and website content, effectively localizing marketing tools and reducing direct marketing expenses by up to 60%.
• Implemented tailored risk management plans for tenders, considering local hospital finance and competitive dynamics, resulting in significant tender wins in France ($1.2M/y) and Sweden ($2M/y).

Took responsibility for the general management of the Generic Onco Hospital Portfolio and Medical Devices across Europe with a P&L responsibility of >300m€.

• Created and implemented a European tender strategy for generic oncology drugs, which led the company to a premium positioning in procurement negotiations in many European countries with a minimal profit of 40%.
• Built a Global Training Academy and provided country-tailored medical and commercial courses, resulting in well-trained sales forces and brand managers. This contributed to a continuous sales growth of >10% in Europe over a 7-year period.

Conducted comprehensive evaluations of strategic product interests and business development initiatives to align with corporate goals. Directed the creation of a differentiated innovative, biosimilar and generic portfolio by selecting optimal dose forms and concentrations for intravenous oncology drugs.

• Achieved market leadership in the generic hospital business through strategic portfolio management and product innovation.
• Enhanced competitive positioning by identifying and capitalizing on unique market opportunities in the BELUX region.

Directed result-oriented management of the hospital business unit, overseeing a €20 million P&L with a focus on financial health and strategic growth. Led a team of 8 senior employees, fostering a culture of high performance and effective people management.

• Successfully navigated a competitor's stock-out situation, resulting in a 200% achievement of the annual sales target.
• Ensured the continuity of critical cancer patient treatments through strategic planning and operational excellence.

Strategically defined the business plans for generic hospital products and medical devices within the BELUX market. Successfully managed the launch of 15 oncology products, overseeing all aspects from licensing to market introduction. Directed efficient product life cycle management, ensuring sustained market relevance and profitability.

• Collaborated with the Global R&D engineers to guide the development of a key component for a premium closed system transfer device, ChemFort/OnGuard and facilitated the product's compatibility with standard protocols for the safe preparation and administration of hazardous drugs.
• Contributed to the product's successful launch in European and American markets, adhering to stringent regulatory standards. Played a pivotal role in expanding the product's global footprint, now available in over 33 countries.

Supervised the sterile (onco)production unit and team of a 480-bed hospital, ensuring GMP, product safety and compliance. Managed decentralized pharmaceutical stocks on technical wards, optimizing inventory levels and reduce financial losses. Coordinated daily operations of the pharmacy department, streamlining processes for efficiency and effectiveness. Oversaw people management responsibilities for 22 employees over a two-year period, fostering a collaborative and productive work environment. Served as president and active member on several scientific committees, contributing to the advancement of pharmaceutical practices.

• Led the establishment of Belgium's first clean-room and center of excellence for the preparation of tailored intravenous hazardous (onco)drugs.
• Implemented the use of a closed system transfer device, significantly enhancing staff protection against occupational exposure.
• Presentation at Gerpac Congress, France: "Construction d'une salle blanche" (2003).